|Articles|March 8, 2017

Tufts CSDD Releases Results of New Impact Report

A recently completed study reported that the 505(b)(2) approval pathway for new drug applications in the US has not led to shorter approval times.

A recently completed study conducted by Tufts CSDD reported that the 505(b)(2) approval pathway for new drug applications in the US, aimed at avoiding the duplication of studies performed on a previously approved drugs, has not led to shorter approval times.

Read the full release here

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Tufts CSDD Releases Results of New Impact Report

Newsletter

Related Content

Imfinzi Regimen Demonstrates 22% Survival Benefit in Early Gastric and GEJ Cancer

ACT Brief: AI Partnerships, Data-Driven Site Activation, and FDA Approval for Omvoh’s Single-Injection Regimen

Using Global Patient Data to Design Smarter, More Inclusive Clinical Trials

Thermo Fisher, Lundbeck Announce New OpenAI Partnerships Advancing AI in Drug Development

ACT Brief: AI Expands Global Site Leadership as Ozempic Shows Potential to Reverse Biological Age

Trending on Applied Clinical Trials Online

Thermo Fisher, Lundbeck Announce New OpenAI Partnerships Advancing AI in Drug Development

ACT Brief: AI Partnerships, Data-Driven Site Activation, and FDA Approval for Omvoh’s Single-Injection Regimen

Imfinzi Regimen Demonstrates 22% Survival Benefit in Early Gastric and GEJ Cancer

Using Global Patient Data to Design Smarter, More Inclusive Clinical Trials

Accelerating Site Payments with Agentic AI: See it in Action